Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia
The developed popPK model, together with corresponding simulations, supports TV-46000 as a LASCA that offers flexible dosing intervals (q1m or q2m) and administration sites (abdomen or upper arm) and does not require oral supplementation or loading dose(s).
Authors
- Yanyan Lin (ORCID: https://orcid.org/0000-0002-5758-0574)
- Floris Fauchet
- Nele Plock (ORCID: https://orcid.org/0000-0002-2025-4441)
- Eline van Maanen
- A. Merenlender Wagner
- Anna Elgart
- Farina Hellmann
- Itay Perlstein
- Rajendra Singh (ORCID: https://orcid.org/0000-0003-2719-4573)
- Anthe S. Zandvliet
Institutions
- Teva Pharmaceuticals (Israel) (IL)
- Certara (United States) (US)
- Teva Pharmaceuticals (United States) (US)
Publication Details
- Journal
- Neurology and Therapy
- Published
- 2025-03-23
- DOI
- https://doi.org/10.1007/s40120-025-00723-z
- Citations
- 5
- Primary Topic
- Schizophrenia research and treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.36